Literature DB >> 15954516

Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum?

Nikita Hegde1, Charina Gayomali, Michael W Rich.   

Abstract

This report describes a case of aseptic meningitis induced by the tumor necrosis factor-alpha inhibitor infliximab. The patient, a 51-year-old female, was being treated for Crohn's disease. After an infliximab infusion, she had headache, fever, arthralgia, myalgia, and meningismus. Cerebrospinal fluid analysis was remarkable for a neutrophilic pleocytosis and elevated protein. Other potential causes of meningitis were excluded. Her symptoms completely resolved within 24 hours of presentation. Because infliximab commonly causes headache and is very immunogenic, we infer that infliximab-induced meningitis is immune-mediated and underrecognized. Potential risk factors and means for minimizing its occurrence are offered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15954516     DOI: 10.1097/01.SMJ.0000155499.21189.75

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  7 in total

1.  Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease.

Authors:  R Quispel; H B van der Worp; M Pruissen; M E Schipper; B Oldenburg
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

Review 2.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

3.  Bacterial meningitis associated with infliximab.

Authors:  Raymond Farah; Svetlana Lisitsin; Moshe Shay
Journal:  Pharm World Sci       Date:  2006-09-27

4.  Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis.

Authors:  Yuki Matsuura-Otsuki; Takaaki Hanafusa; Hiroo Yokozeki; Kyoko Watanabe
Journal:  Case Rep Dermatol       Date:  2017-05-22

5.  Infliximab-Induced Aseptic Meningitis in a Patient with Crohn's Disease.

Authors:  Zachary Junga; Brett Theeler; Manish Singla
Journal:  ACG Case Rep J       Date:  2018-06-20

6.  Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events.

Authors:  Amy Kunchok; Allen J Aksamit; John M Davis; Orhun H Kantarci; B Mark Keegan; Sean J Pittock; Brian G Weinshenker; Andrew McKeon
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

7.  Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.

Authors:  Akira Arakawa; Masaki Iizuka; Shunichi Matsuda; Erika Matsubara; Hiroki Yamazaki; Noritada Yoshikawa; Hirotoshi Tanaka; Toshihiro Yoshizawa
Journal:  Intern Med       Date:  2021-07-03       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.